In our study, four out of six patients had MAS at the onset of sJIA, and in the rest two it occurred during relapse. Two patients with MAS developed full-blown clinical picture while another four had incomplete clinical features with minor laboratory alteration. Due to the use of diff erent diagnostic guidelines, we found diff erence in the prevalence of MAS. It was slightly higher in comparison to available studies, while other researched features, such as clinical characteristics, were similar.
Introduction
Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA), caused by an exaggerated but ineff ective immune response involving excessive macrophage and T cell activation, followed by high production of proinfl ammatory cytokines [1] [2] [3] . Th e cardinal clinical symptoms and signs are prolonged high fever, hepatosplenomegaly, neurologic dysfunction, and hemorrhagic manifestations. Characteristic laboratory abnormalities include pancytopenia, elevated levels of serum liver enzymes, triglycerides, lactate dehydrogenase, ferritin, and low levels of fi brinogen. Although macrophage hemophagocytosis is often seen on bone marrow examination, in the initial stages of the syndrome this fi nding may be absent 4, 5 . Th e reported mortality rates of MAS reach 20%-30%, but the outcome can be improved by early diagnosis and prompt initia-tion of life-saving treatment 3 . Th e estimated prevalence of MAS in sJIA is 10%. However, recent evidence suggests that the syndrome may occur subclinically in an additional 30%-40% of sJIA patients 6, 7 . Because MAS is similar to the group of histiocytic disorders belonging to hemophagocytic lymphohistiocytosis (HLH), it is currently classifi ed among the secondary, or acquired, forms of HLH 8, 9 . Th ree sets of guidelines are currently available for diagnosing MAS in patients with sJIA, as follows: diagnostic guidelines for HLH (HLH-2004) , which were primarily developed for homozygous genetic disorders 10 ; preliminary diagnostic guidelines for MAS complicating sJIA from 2005 11 ; and the new set of classifi cation criteria for MAS complicating sJIA from 2016, based on a combination of expert consensus, available evidence from medical literature, and analysis of real patient data 12 .
Patients and Methods
A retrospective study was carried out at the Department of Pediatrics, Division of Immunology and Rheumatology, Zagreb University Hospital Centre, in the period from 2009 to 2015. Th e study included 35 children aged 1-18 diagnosed with sJIA according to ILAR criteria 13 . Epidemiological and clinical data were obtained from patient records. Demographic information included gender, date of birth, age at onset of sJIA and age at onset of MAS. Clinical data included fever, hepatomegaly, splenomegaly, hemorrhagic manifestations, lymphadenopathy, active arthritis, central nervous system (CNS) involvement and serositis. Extensive laboratory workup was performed on all patients (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complete blood count, aspartate aminotransferase (AST), alanine aminotransferase, fi - 
Results
Systemic JIA was diagnosed in 35 children, 23 boys and 12 girls, mean age (±SD) 5.51±3.65 years. Eight of 35 patients had fl are of sJIA. At the disease onset, all patients presented with fever, evanescent rash and arthritis. Th e most consistent symptoms were hepatomegaly (8/35) and splenomegaly (4/35). All patients with fl are of sJIA also presented with fever and evanescent rash, and half of them had hepatomegaly. Infl ammation markers (ESR and CRP) were elevated in all patients at disease onset and in fl are (Table 1) .
With the use of guidelines from 2005, MAS was diagnosed in six (6/35, 17.1%) patients with sJIA. In four of them, it occurred at the onset of sJIA during fi rst hospitalization and in the remaining two patients, it occurred during fl are. With the new set of criteria from 2016, MAS was diagnosed in four (4/35, 11.4%) patients with sJIA. In three of them, it occurred during fi rst hospitalization, and in one patient it occurred during fl are. MAS was not diagnosed with the HLH-2004 guidelines. Fever (6/6) and hepatomegaly (5/6) were the most common clinical criteria recorded in patients with MAS, followed by splenomegaly and hemorrhages. CNS dysfunction was not recorded. All laboratory values were abnormal, as expected (showing either increased or decreased levels) in patients with MAS when compared with sJIA patients (Table 1) .
Discussion
We literature data where the prevalence of MAS in sJIA is 10%, and with recent evidence suggesting the possibility of subclinical occurrence in an additional 30%-40% of sJIA patients 6, 7 . Macrophage activation syndrome generally develops in earlier phases of the underlying disease, or may be the presenting manifestation of sJIA. In our study, four out of six patients had MAS at the onset of sJIA, during fi rst hospitalization, and in two out of six patients it occurred during fl are.
Typically, patients with MAS become acutely ill with sudden onset of nonremitting high fever, profound depression in all 3 blood cell lines (i.e. leukopenia, anemia and thrombocytopenia), hepatosplenomegaly, lymphadenopathy, and elevated serum liver enzyme levels. In our study, two of 35 patients had full-blown clinical picture of MAS, with laboratory test values in line with expectations, showing absolute decline and typical changes that occur in the syndrome. Another four of 35 patients had incomplete clinical features and relative decline in these laboratory parameters in comparison with sJIA patients.
Clinical symptoms are often delayed or similar to confusable conditions such as infections, sepsis and fl are of underlying disease. Comparing the criteria, it is obvious that the majority of our patients satisfi ed the criteria from 2005, which include clinical manifestations such as hepatomegaly and hemorrhages. Notably, fi ve out of six patients with MAS had hepatomegaly. However, hepatomegaly was present in half (4/8) of patients with sJIA fl are and in eight (8/35) patients at the onset of sJIA, probably because mild hepatomegaly is a frequent feature of active sJIA.
Th e prevalence of all laboratory MAS criteria was much greater in patients with MAS comparing to sJIA. Hyperferritinemia is an important laboratory hallmark of MAS, therefore, it is mandatory in the new set of classifi cation criteria (ferritin >684 ng/mL). In our study, patients with MAS had signifi cantly increased ferritin levels; they all met the previously mentioned condition, whereas patients at the onset of sJIA and fl are of sJIA did not. In the new set of MAS criteria, platelet count and fi brinogen levels are within the normal range of laboratory tests and the levels of AST and triglycerides are only slightly above the normal limits. In contrast, children with active sJIA usually have signifi cantly increased platelet counts and fi brinogen levels, and normal levels of AST and triglycer-ides 12, 14 . In our study, most of the MAS patients had slightly decreased platelet count, slightly increased AST and triglycerides, while the levels of fi brinogen and leukocytes were within the normal range.
Our results should be interpreted in the light of some potential limitations, primarily the small number of MAS patients. However, we would like to point out that we were dealing with the disease that is not considered common. Patient data were collected through retrospective review of clinical charts. We had incomplete laboratory data for triglycerides and fi brinogen, which both are part of the guidelines.
In conclusion, due to the use of diff erent diagnostic guidelines, we found a diff erence in the prevalence of MAS. It was slightly higher in comparison to available studies, while other investigated features, such as clinical characteristics, were similar. It is important to make a timely diagnosis of MAS, usually by clinical expert opinion and detection of subtle laboratory alterati on before the occurrence of full-blown clinical picture which, if untreated, leads to fatal outcome.
